Асосий контентга ўтиш
AkademIndex

Маҳсулотлар

Ишлаб чиқувчилар учун

AkademBaseЭкотизим учун очиқ API
← Ишга қайтиш

Ушбу иш иқтибос қилган ишлар

27 та иш

Иш: Scaling Up Molecular Diagnostic Tests for Drug-Resistant Tuberculosis in Uzbekistan from 2012–2019: Are We on the Right Track?

  1. Multidrug-resistant tuberculosis in Uzbekistan: results of a nationwide survey, 2010 to 2011

    Dilrabo Ulmasova, G Uzakova, M N Tillyashayhov +17

    МақолаTuberculosis Research and EpidemiologyEurosurveillance201315 иқтибос
    ABI

  2. Uzbekistan: health system review.

    Mohir Ahmedov, Ravshan Azimov, Zulkhumor Mutalova +3

    МақолаHealthcare Systems and ReformsPubMed201413 иқтибос
    ABI

  3. Multidrug-Resistant Tuberculosis Treatment Outcomes in Karakalpakstan, Uzbekistan: Treatment Complexity and XDR-TB among Treatment Failures

    Helen Cox, Stobdan Kalon, Sholpan Allamuratova +6

    Мақола200711 иқтибос
    ABI

  4. Treatment of Highly Drug-Resistant Pulmonary Tuberculosis

    Francesca Conradie, Andreas H. Diacon, Nosipho Ngubane +15

    Мақола20207 иқтибос
    ABI

  5. Сарлавҳасиз

    Бошқа6 иқтибос
    ABI

  6. Rapid Molecular Detection of Tuberculosis and Rifampin Resistance

    Catharina Boehme, Pamela Nabeta, Doris Hillemann +16

    Мақола20104 иқтибос
    ABI

  7. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies

    Erik von Elm, Douglas G. Altman, Matthias Egger +4

    Мақола20074 иқтибос
    ABI

  8. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for reporting observational studies

    Erik von Elm, Douglas G. Altman, Matthias Egger +3

    Мақола20143 иқтибос
    ABI

  9. Modelling the effect of short-course multidrug-resistant tuberculosis treatment in Karakalpakstan, Uzbekistan

    James M. Trauer, Jay Achar, Nargiza Parpieva +7

    МақолаTuberculosis Research and EpidemiologyBMC Medicine20163 иқтибос
    ABI

  10. Person-centred care in practice: perspectives from a short course regimen for multi-drug resistant tuberculosis in Karakalpakstan, Uzbekistan

    Shona Horter, Beverley Stringer, Nell Gray +5

    МақолаTuberculosis Research and EpidemiologyBMC Infectious Diseases20203 иқтибос
    ABI

  11. Tuberculosis control in prisons: current situation and research gaps

    Masoud Dara, Colleen Acosta, Natalie V. S. Vinkeles Melchers +8

    Шарҳ мақола20152 иқтибос
    ABI

  12. Tuberculosis, social determinants and co-morbidities (including HIV)

    Raquel Duarte, Knut Lönnroth, Cláudia Carvalho +4

    Шарҳ мақола20172 иқтибос
    ABI

  13. Challenges and Progress with Diagnosing Pulmonary Tuberculosis in Low- and Middle-Income Countries

    Anthony Harries, Ajay Kumar

    Шарҳ мақола20182 иқтибос
    ABI

  14. Xpert<sup>®</sup> MTB/RIF for national tuberculosis programmes in low-income countries: when, where and how?

    Arnaud Trébucq, Donald A. Enarson, Chen‐Yuan Chiang +9

    Мақола20112 иқтибос
    ABI

  15. Implementing the Xpert® MTB/RIF Diagnostic Test for Tuberculosis and Rifampicin Resistance: Outcomes and Lessons Learned in 18 Countries

    Elisa Ardizzoni, Emmanuel Fajardo, Peter Saranchuk +5

    Мақола20152 иқтибос
    ABI

  16. Has the utilisation of Xpert <sup>®</sup> MTB/RIF in Manicaland Province, Zimbabwe, improved with new guidance on whom to test?

    A. Jokwiro, Collins Timire, Anthony Harries +5

    Мақола20182 иқтибос
    ABI

  17. Сарлавҳасиз

    Бошқа1 иқтибос
    ABI

  18. Сарлавҳасиз

    Бошқа1 иқтибос
    ABI

  19. Сарлавҳасиз

    Бошқа1 иқтибос
    ABI

  20. Сарлавҳасиз

    Бошқа1 иқтибос
    ABI

  21. Сарлавҳасиз

    Бошқа1 иқтибос
    ABI

  22. Сарлавҳасиз

    Бошқа1 иқтибос
    ABI

  23. Сарлавҳасиз

    Бошқа1 иқтибос
    ABI

  24. Сарлавҳасиз

    Бошқа1 иқтибос
    ABI

  25. Сарлавҳасиз

    Бошқа1 иқтибос
    ABI